According to recent phase 3 randomized trials, a<unk> –clopidogrel combination is safe and has been found to be more effective than standard clopidogrel treatment at reducing ischemic events in the heart, without increasing major bleeding in the treatment of stenotic coronary arteries. The advantages of this drug combination are most prominent in patients with myocardial infarction. Available antiplatelet drugs have delayed onset and offset of action. Since<unk> ’s effects are immediate and quickly reversed, it is a more desirable drug for elective treatment of stenotic coronary arteries, high risk acute coronary syndromes treated with immediate coronary stenting, and for bridging those surgery patients who require P2Y12 inhibition. Current evidence regarding<unk>  therapy is limited by the lack studies assessing<unk>  administration in conjunction with either prasugrel or ticagrelor. Recently, it's been approved for adult patients undergoing percutaneous coronary intervention (PCI).
Cangrelor
Cetrorelix
Riociguat
Vericiguat
Prokarin
Prasugrel
Coronaridine
Aprepitant